Shoulder humeral components – Prescribed List post-listing review

We are reviewing the groupings of shoulder humeral components on the Prescribed List (PL).

What the review is about 

Shoulder humeral components are used in surgery of the shoulder joint. 

In 2020, the Prostheses List Advisory Committee (PLAC) – now Medical Devices and Human Tissue Advisory Committee (MDHTAC) – and the Specialist Orthopaedic Expert Clinical Advisory Group (SOECAG) discussed that there are different humeral trays and inserts for reverse shoulder systems with different designs and constructs.  

SOECAG advised that due to developments in designs of shoulder joint replacement devices, there had been somewhat of an overlap in how reverse shoulder components have been historically grouped.

In May 2025, MDHTAC advised the department to proceed with a post-listing review (PLR) of the subgroups and suffixes and respective benefits for the humeral trays and inserts. The objective of this PLR is to review the current functionality and designs of humeral trays, metaphyseal components and humeral cups to determine the appropriate PL settings. 

The devices that are in scope of the review are: 

  • 06.02.04.04 – Shoulder – Humeral – Modular humeral component – metaphyseal, cemented 
  • 06.02.04.05 – Shoulder – Humeral – Modular humeral component – metaphyseal, uncemented  
  • 06.02.04.14 – Shoulder – Humeral – Humeral cup 
  • 06.02.05.04 – Shoulder – Glenoid – Glenoid insert 
  • 06.02.06.07 – Shoulder – Accessories – Reverse humeral tray. 

The review process 

The review will follow the process outlined in the post-listing review framework

The review will explore the following questions:  

  1. Are the current billing codes grouped according to similar device characteristics that reflect their use within implant constructs? 
  2. Is there robust comparative clinical evidence that would justify appropriate PL benefits for components with specific device characteristics (e.g. inlay versus onlay conformation)?
  3. What PL groupings best reflect clinical and/or functional similarity? 
  4. Using the proposed grouping structure, what are the appropriate PL benefits for the devices in scope?

Timeline

Date 

Activity 

June 2026 Invite stakeholders to provide information
June – Sept 2026  External consultant to draft report   
Sept – Oct 2026 Stakeholder consultation  
November 2026 Final report  
December 2026 MDHTAC advice  

Result of the review 

This review is ongoing. We will release the outcome when the review is complete. 

Contact

Prescribed List post-listing reviews

Please contact us for more information about post-listing reviews of products on the Prescribed List.
Date last updated: